{"title":"日本三级保健癌症中心社区获得性呼吸道病毒感染负担及其对癌症治疗的影响","authors":"Takahiro Fujita, Takeharu Iida","doi":"10.1016/j.jiac.2025.102822","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To clarify the burden of community-acquired respiratory virus (CRV) other than SARS-CoV-2 infections in adult patients with cancer and their impact on cancer treatment.</p><p><strong>Patients and methods: </strong>We retrospectively examined positive cases using multiplex respiratory polymerase chain reaction panel tests at a Japanese tertiary-care cancer center. From April 2023 to March 2024, a total of 1629 tests were performed on 1068 patients.</p><p><strong>Results: </strong>CRV other than SARS-CoV-2 were identified in 128 cases. These include rhinovirus/enterovirus (47 cases), parainfluenza virus (22 cases), human coronavirus (18 cases), Respiratory syncytial virus (15 cases), influenza A (14 cases), and human metapneumovirus (10 cases). Pneumonia was observed in 19 (15.7 %) patients. In 38 patients (31.4 %), cancer treatment was postponed due to CRV other than SARS-CoV-2 infection.</p><p><strong>Conclusion: </strong>CRV other than SARS-CoV-2infections contribute to delays in cancer treatment and are frequently associated with pneumonia. To ensure the safe continuation of cancer treatment, it is imperative to provide patients with appropriate infection control guidance and perform respiratory panel tests for an accurate diagnosis.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102822"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burden of community-acquired respiratory virus infections and impact on cancer treatment at a tertiary care cancer center in Japan.\",\"authors\":\"Takahiro Fujita, Takeharu Iida\",\"doi\":\"10.1016/j.jiac.2025.102822\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To clarify the burden of community-acquired respiratory virus (CRV) other than SARS-CoV-2 infections in adult patients with cancer and their impact on cancer treatment.</p><p><strong>Patients and methods: </strong>We retrospectively examined positive cases using multiplex respiratory polymerase chain reaction panel tests at a Japanese tertiary-care cancer center. From April 2023 to March 2024, a total of 1629 tests were performed on 1068 patients.</p><p><strong>Results: </strong>CRV other than SARS-CoV-2 were identified in 128 cases. These include rhinovirus/enterovirus (47 cases), parainfluenza virus (22 cases), human coronavirus (18 cases), Respiratory syncytial virus (15 cases), influenza A (14 cases), and human metapneumovirus (10 cases). Pneumonia was observed in 19 (15.7 %) patients. In 38 patients (31.4 %), cancer treatment was postponed due to CRV other than SARS-CoV-2 infection.</p><p><strong>Conclusion: </strong>CRV other than SARS-CoV-2infections contribute to delays in cancer treatment and are frequently associated with pneumonia. To ensure the safe continuation of cancer treatment, it is imperative to provide patients with appropriate infection control guidance and perform respiratory panel tests for an accurate diagnosis.</p>\",\"PeriodicalId\":16103,\"journal\":{\"name\":\"Journal of Infection and Chemotherapy\",\"volume\":\" \",\"pages\":\"102822\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infection and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jiac.2025.102822\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jiac.2025.102822","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Burden of community-acquired respiratory virus infections and impact on cancer treatment at a tertiary care cancer center in Japan.
Aim: To clarify the burden of community-acquired respiratory virus (CRV) other than SARS-CoV-2 infections in adult patients with cancer and their impact on cancer treatment.
Patients and methods: We retrospectively examined positive cases using multiplex respiratory polymerase chain reaction panel tests at a Japanese tertiary-care cancer center. From April 2023 to March 2024, a total of 1629 tests were performed on 1068 patients.
Results: CRV other than SARS-CoV-2 were identified in 128 cases. These include rhinovirus/enterovirus (47 cases), parainfluenza virus (22 cases), human coronavirus (18 cases), Respiratory syncytial virus (15 cases), influenza A (14 cases), and human metapneumovirus (10 cases). Pneumonia was observed in 19 (15.7 %) patients. In 38 patients (31.4 %), cancer treatment was postponed due to CRV other than SARS-CoV-2 infection.
Conclusion: CRV other than SARS-CoV-2infections contribute to delays in cancer treatment and are frequently associated with pneumonia. To ensure the safe continuation of cancer treatment, it is imperative to provide patients with appropriate infection control guidance and perform respiratory panel tests for an accurate diagnosis.
期刊介绍：
The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
